BioAge Labs, Inc. (BIOA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BioAge Labs, Inc. (BIOA) Healthcare & Pipeline Overview

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in metabolic disease therapeutics. Utilizing a proprietary technology platform and human datasets, BioAge identifies molecular targets linked to aging, developing innovative treatments like azelaprag for obesity and BGE-100 for neuroinflammation, positioning it within the competitive biotechnology sector.

What Is the Investment Thesis for BIOA?

BioAge Labs presents a notable research candidate within the biotechnology sector, driven by its innovative approach to developing therapeutics for metabolic diseases. The company's focus on aging-related molecular pathways, combined with its proprietary human dataset platform, offers a differentiated approach to drug discovery. Key value drivers include the clinical progress of azelaprag, currently in Phase 1 and Phase 2 trials for obesity, and BGE-100, targeting neuroinflammation. Successful clinical trial outcomes and potential partnerships could significantly increase the company's market capitalization, which currently stands at $0.67 billion. However, the company's negative profit margin of -896.1% highlights the risks associated with clinical-stage biopharmaceutical companies, including regulatory hurdles and the potential for clinical trial failures. The company's high beta of 1.83 suggests higher volatility compared to the overall market.

Based on FMP financials and quantitative analysis

BIOA Key Highlights

Market capitalization of $365M reflects investor valuation of BioAge Labs' pipeline and technology platform.

• Gross margin of 99.2% indicates strong potential profitability upon successful commercialization of drug candidates.
• Profit margin of -896.1% highlights the significant R&D expenses and lack of revenue typical for a clinical-stage biopharmaceutical company.
• Beta of 1.83 suggests higher volatility compared to the overall market, reflecting the inherent risks in biotechnology investments.
• Focus on aging-related targets differentiates BioAge Labs in the competitive biotechnology landscape.

Who Are BIOA's Competitors?

BIOA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BIOA's Key Strengths?

Innovative technology platform for identifying aging-related drug targets.

• Clinical-stage pipeline with drug candidates targeting significant unmet medical needs.
• Strong focus on human datasets for target validation.
• Experienced management team with expertise in drug development.

What Are BIOA's Weaknesses?

High R&D expenses and negative profit margin.

• Reliance on successful clinical trial outcomes.
• Limited commercialization experience.
• Potential competition from larger pharmaceutical companies.

What Could Drive BIOA Stock Higher?

BIOA catalyst: Phase 2 clinical trial results for azelaprag in combination with tirzepatide for obesity in older adults (expected in late 2026).

• Initiation of Phase 2 clinical trials for BGE-100 in neuroinflammation (expected in late 2026).
• Expansion of BioAge's proprietary human datasets to identify new drug targets.
• Potential strategic partnerships with larger pharmaceutical companies for drug development and commercialization.

What Are the Key Risks for BIOA?

Negative return on equity (-29.4%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for azelaprag or BGE-100.
• Regulatory hurdles and delays in obtaining FDA approval.
• Competition from other biotechnology companies developing similar therapeutics.
• High R&D expenses and negative profit margin.
• Patent expiration and generic competition for approved drugs.

What Are the Growth Opportunities for BIOA?

• Expansion of Azelaprag Clinical Trials: BioAge has the opportunity to expand the clinical trials for Azelaprag beyond obesity to include other metabolic disorders. The global market for obesity treatment is projected to reach $45 billion by 2030. Successful clinical trials and regulatory approval could lead to significant revenue generation for BioAge, potentially capturing a substantial share of this growing market. This expansion could begin as early as 2027, following the completion of ongoing Phase 2 trials.
• Development of BGE-100 for Neuroinflammation: BGE-100, BioAge's NLRP3 antagonist, targets diseases driven by neuroinflammation. The market for neuroinflammation therapeutics is estimated at $12 billion, with potential for significant growth as the understanding of neuroinflammatory diseases expands. Advancing BGE-100 through clinical trials and securing regulatory approval could provide BioAge with a valuable asset in this growing market. Phase 2 trials are expected to commence in late 2026.
• Strategic Partnerships and Collaborations: BioAge can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Collaborations could provide access to additional funding, expertise, and distribution networks, enhancing BioAge's ability to bring its products to market. Such partnerships are common in the biotechnology industry, and BioAge's unique technology platform and promising pipeline make it an attractive partner. Discussions are expected to begin in 2027.
• Leveraging Proprietary Human Datasets: BioAge's differentiated human datasets provide a competitive advantage in identifying novel drug targets. The company can leverage these datasets to expand its pipeline and develop new therapeutics for a range of age-related diseases. This data-driven approach can accelerate the drug discovery process and increase the likelihood of success. The company plans to expand its datasets by 2028.
• Expansion into New Therapeutic Areas: BioAge can leverage its expertise in aging-related molecular pathways to expand into new therapeutic areas beyond metabolic diseases and neuroinflammation. This could include areas such as cardiovascular disease, oncology, and regenerative medicine, offering significant growth potential. The company's technology platform can be adapted to identify novel targets in these areas, providing a diversified pipeline and reducing reliance on specific therapeutic areas. This expansion is projected to start in 2029.

What Are BIOA's Competitive Advantages?

• Proprietary Technology Platform: BioAge's platform leverages human datasets to identify aging-related targets, providing a unique approach to drug discovery.
• Differentiated Human Datasets: The company's access to and analysis of human datasets offer a competitive advantage in identifying novel drug targets.
• Clinical-Stage Pipeline: BioAge's pipeline includes drug candidates in various stages of clinical development, reducing the risk associated with early-stage research.
• Expertise in Aging Biology: The company's focus on aging-related molecular pathways provides a specialized expertise in a growing field of research.

What Does BIOA Do?

BioAge Labs, Inc., founded in 2015 and based in Richmond, California, is a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions for metabolic diseases. The company's core strategy revolves around its unique technology platform, which leverages extensive human datasets to pinpoint molecular changes that drive aging. This approach allows BioAge to identify novel targets for therapeutic intervention, setting it apart in the competitive biotechnology landscape. BioAge's pipeline features several promising drug candidates. Azelaprag, an orally available small molecule, is currently in Phase 1 clinical trials for the treatment of obesity. Furthermore, a Phase 2 clinical trial has been initiated to evaluate the efficacy of azelaprag in combination with tirzepatide for treating obesity in older adults. The company is also developing BGE-100, an orally available, brain-penetrant NLRP3 antagonist designed to treat diseases driven by neuroinflammation. By focusing on age-related molecular pathways, BioAge aims to address significant unmet medical needs in metabolic and neurological disorders, positioning itself as an innovator in the field of aging-related therapeutics.

What Products and Services Does BIOA Offer?

• Develop therapeutic product candidates for metabolic diseases.
• Utilize a technology platform to identify targets based on molecular changes that drive aging.
• Develop azelaprag, an orally available small molecule for the treatment of obesity.
• Initiate phase 2 clinical trial of azelaprag in combination with tirzepatide for obesity treatment in older adults.
• Develop BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist.
• Target diseases driven by neuroinflammation with BGE-100.

How Does BIOA Make Money?

• Develop and patent novel therapeutic compounds.
• Conduct preclinical and clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Potentially partner with larger pharmaceutical companies for commercialization.
• Generate revenue through licensing agreements or direct sales of approved drugs.

What Industry Does BIOA Operate In?

BioAge Labs operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market for metabolic disease therapeutics is substantial and growing, driven by the increasing prevalence of obesity and related conditions. The company's focus on aging-related molecular pathways positions it within a niche segment of the market, offering potential advantages in identifying novel drug targets. Competition includes established pharmaceutical companies and other biotechnology firms developing treatments for metabolic and neurological disorders. The industry is subject to ongoing technological advancements and shifting regulatory landscapes, requiring companies to adapt and innovate to maintain a competitive edge.

Who Are BIOA's Key Customers?

• Patients suffering from metabolic diseases like obesity.
• Patients suffering from diseases driven by neuroinflammation.
• Healthcare providers who prescribe BioAge's therapeutics.
• Pharmaceutical companies interested in licensing or acquiring BioAge's drug candidates.

BioAge Labs, Inc. (BIOA) Valuation Context

Valued at $365M, BIOA is classified as a small-cap stock. Relative to its peer group, BIOA's quantitative score of 23/100 is below the peer average of 79/100.

BIOA Revenue & Earnings Trend

In Q2 2026, BIOA generated $2.5M in top-line revenue, marking a sequential decrease of 11.6%. The company recorded a net loss of $26.1M, with diluted EPS of $-0.58. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, BIOA averaged $-0.59 in diluted EPS.

Company Profile

BioAge Labs, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Emeryville, US. The company is led by CEO Kristen Fortney. BIOA has traded publicly since 2024.

Return on equity for BioAge Labs, Inc. stands at -29.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -22.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 24.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.7%, the inverse of the P/E and a quick read on earnings relative to price.

BioAge Labs, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.85 places it in the safe zone, indicating low near-term bankruptcy risk.

Wall Street analysts project BioAge Labs, Inc. revenue of about $7.6M for fiscal 2026, with EPS near $-2.43. The estimate reflects 8 contributing analysts.

BIOA Financials

BIOA Latest News

BIOA Analyst Consensus

BIOA MoonshotScore

What Investors Ask About BioAge Labs, Inc. (BIOA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources